Zacks Research Issues Positive Forecast for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Investment analysts at Zacks Research raised their Q1 2026 earnings per share (EPS) estimates for shares of Corcept Therapeutics in a research report issued on Wednesday, April 2nd. Zacks Research analyst K. Das now anticipates that the biotechnology company will earn $0.47 per share for the quarter, up from their previous forecast of $0.45. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.11). The company had revenue of $181.89 million for the quarter, compared to analyst estimates of $200.12 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%.

A number of other equities research analysts have also weighed in on the stock. Piper Sandler boosted their price objective on shares of Corcept Therapeutics from $128.00 to $131.00 and gave the company an “overweight” rating in a report on Thursday, April 3rd. HC Wainwright boosted their price target on Corcept Therapeutics from $115.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, March 31st. Canaccord Genuity Group increased their price objective on Corcept Therapeutics from $130.00 to $142.00 and gave the company a “buy” rating in a report on Tuesday, April 1st. StockNews.com downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, February 28th. Finally, Truist Financial increased their price target on shares of Corcept Therapeutics from $76.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, March 31st. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Corcept Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $143.25.

Corcept Therapeutics Stock Up 0.3 %

NASDAQ:CORT opened at $74.65 on Monday. The company’s 50 day moving average is $65.10 and its two-hundred day moving average is $56.73. The company has a market cap of $7.88 billion, a PE ratio of 59.25 and a beta of 0.15. Corcept Therapeutics has a twelve month low of $20.84 and a twelve month high of $117.33. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01.

Insider Activity

In related news, CEO Joseph K. Belanoff sold 2,924 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $60.91, for a total value of $178,100.84. Following the completion of the transaction, the chief executive officer now directly owns 3,019,411 shares in the company, valued at $183,912,324.01. The trade was a 0.10 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $68.08, for a total transaction of $149,776.00. The disclosure for this sale can be found here. Insiders sold a total of 163,124 shares of company stock valued at $15,074,318 in the last quarter. 20.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Corcept Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Norges Bank acquired a new stake in Corcept Therapeutics in the fourth quarter valued at approximately $42,055,000. GAMMA Investing LLC lifted its position in shares of Corcept Therapeutics by 12,888.9% during the 1st quarter. GAMMA Investing LLC now owns 389,148 shares of the biotechnology company’s stock valued at $44,448,000 after buying an additional 386,152 shares in the last quarter. Braun Stacey Associates Inc. acquired a new stake in Corcept Therapeutics in the 4th quarter valued at $14,935,000. Synergy Asset Management LLC increased its holdings in Corcept Therapeutics by 131.3% in the 4th quarter. Synergy Asset Management LLC now owns 462,411 shares of the biotechnology company’s stock worth $22,369,000 after acquiring an additional 262,503 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Corcept Therapeutics during the fourth quarter worth $12,084,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.